How to Switch from Wegovy to Zepbound (Tirzepatide)

SURMOUNT-5 was the trial the weight loss field had been waiting for — a direct head-to-head comparison of the two most effective GLP-1 medications. The results were decisive:

The bottom line: Tirzepatide produced 47% more weight loss than semaglutide. Patients on tirzepatide were more than twice as likely to achieve ≥25% body weight loss. This is not a marginal difference — it's a clinically significant superiority. See our full Zepbound vs Wegovy comparison for more details.

Why the difference? Tirzepatide is a dual GIP + GLP-1 receptor agonist, while semaglutide targets GLP-1 only. The GIP component adds metabolic benefits that translate to greater weight reduction, improved insulin sensitivity, and enhanced fat metabolism. For a different approach, you might also consider switching from Wegovy to Foundayo (oral, lower cost).

Not every Wegovy patient needs to switch. Here's when it makes sense:

• Weight loss plateau — You've been on Wegovy 2.4mg for 6+ months and weight loss has stalled below your goal
• Need more than 15% loss — SURMOUNT-5 shows 54% of tirzepatide patients hit ≥20% loss vs only 24% on semaglutide
• Comorbidity-driven goals — Conditions like NASH, severe sleep apnea, or pre-surgical weight targets that require more aggressive weight reduction
• Cost savings — Wegovy costs $1,349/month; Zepbound is $499/month via LillyDirect — a $850/month savings
• Side effect issues on Wegovy — Wegovy's higher nausea rate (44%) vs Zepbound (28%) may be a factor for switching

When to stay on Wegovy: If you've achieved your goal weight and are maintaining well, or if your insurance covers Wegovy but not Zepbound, the switch may not be necessary. For weight maintenance, Foundayo may be an option. See our safe GLP-1 switching guide for general principles.

These are different molecules, so there's no direct mg-to-mg conversion. All patients start Zepbound at 2.5mg regardless of their Wegovy dose:

Transition timing: Take your last Wegovy injection. The following week (on your usual injection day), administer your first Zepbound 2.5mg dose. Semaglutide's 7-day half-life means there's overlap coverage during the first week on Zepbound, minimizing any gap in GLP-1 activity. See our dose equivalence chart for cross-medication comparisons.

Important: Even though you're GLP-1-adapted from Wegovy, the GIP component in Zepbound is new. Starting at 2.5mg and titrating up every 4 weeks minimizes GI side effects from the novel GIP stimulation.

Switching from Wegovy to Zepbound often means fewer GI side effects — a welcome surprise for many patients:

• Nausea: Wegovy 44% → Zepbound 28% — significant improvement
• Diarrhea: Wegovy 30% → Zepbound 23% — improvement
• Vomiting: Wegovy 24% → Zepbound 12% — major improvement
• Constipation: Wegovy 24% → Zepbound 11% — major improvement
• Injection site reactions: Wegovy 6% → Zepbound 3.2% — improvement

Why are Zepbound's side effects lower despite more weight loss? Tirzepatide's dual-agonist mechanism may distribute receptor activation more evenly, reducing the concentrated GI stimulation seen with high-dose semaglutide. Additionally, the GIP component has intrinsic anti-nausea properties. For a different oral option with a mild side effect profile, see Foundayo vs Wegovy.

During the transition: Most patients already adapted to GLP-1 from Wegovy experience minimal additional side effects when starting Zepbound. New GI symptoms, if any, are typically mild and limited to the first 1-2 weeks at each dose level. For exercise guidance during the switch, see our exercise and muscle loss guide.

This switch can save you significant money:

The math is compelling: You get more weight loss (20.2% vs 13.7%), fewer side effects, and save $850/month at self-pay prices. Even with insurance, Zepbound's lower list price may result in lower copays depending on your plan structure. If cost is your main concern, Foundayo at $149-349/month is the most affordable FDA-approved option. See our best GLP-1 without insurance guide for all self-pay options.